Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank62
5Y CAGR-14.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-14.1%/yr
Long-term compound
Percentile
P62
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 32.82% |
| 2024 | 67.39% |
| 2023 | -50.27% |
| 2022 | -16.01% |
| 2021 | 24.79% |
| 2020 | 70.23% |
| 2019 | -39.54% |
| 2018 | 115.36% |
| 2017 | 25.86% |
| 2016 | 60.14% |